Engineering Native E. coli to Detect, Report, and Treat Colorectal Cancer
改造天然大肠杆菌来检测、报告和治疗结直肠癌
基本信息
- 批准号:10330342
- 负责人:
- 金额:$ 68.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-21 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAddressAffectAfrican AmericanAgeAgonistAnimal GeneticsAnimal ModelAttenuatedBacteriaBile AcidsBiological Response Modifier TherapyBiosensorCancer BiologyCancer DetectionCancer EtiologyCaspaseCellsCessation of lifeColonColorectal CancerDataDevelopmentDiagnosisDiseaseDisease ProgressionEngineeringEnvironmentEscherichia coliFamilial Adenomatous Polyposis SyndromeGene ExpressionGenetic EngineeringGenetic ModelsGenetic Predisposition to DiseaseGoalsGrowthHealthIncidenceInflammatory Bowel DiseasesInterdisciplinary StudyInterventionKnowledgeMalignant NeoplasmsMethodsMicrofluidic MicrochipsMissionModelingMonitorMusOrganoidsOutcomePeptide HydrolasesPerformancePopulationPopulation DynamicsProtease InhibitorProteinsProteomicsPublic HealthReporterReportingResearchResearch PersonnelRiskRoleScientistSignal TransductionSystemTestingTherapeuticTherapeutic AgentsTherapeutic UsesTimeTissuesWorkadenomaanticancer researchbasecancer therapycolorectal cancer preventioncolorectal cancer progressioncolorectal cancer screeningcolorectal cancer treatmentdemographicsearly onset colorectal cancerepidemiology studygut microbiotahigh risk populationhost colonizationhost-microbe interactionsimprovedinnovationinterestmathematical modelmicrobial compositionmicrobiomemicroorganismnovelnovel strategiesorgan on a chippredictive testpreventreceptorresponsesensorsynthetic biologytooltraittranslational impacttumortumor microenvironmenttumor progressionvector
项目摘要
PROJECT SUMMARY/ABSTRACT
Despite its overall decreasing occurrence, colorectal cancer (CRC) remains the fourth most common cause
of cancer deaths in the US. Unfortunately, epidemiological studies demonstrate an alarming increase in inci-
dence in populations below the age of 50, who are not routinely screened. Furthermore, CRC detection is difficult
in high-risk groups, including those with a genetic predisposition (e.g. familial adenomatous polyposis), disease
traits (e.g. inflammatory bowel disease), or from certain demographics (e.g. Black-Americans). Thus, there is a
significant need for the development of innovative solutions for the early detection of CRC and the prevention of
the transition from adenoma to CRC. To address this need, our interdisciplinary research team will develop
genetically engineered bacteria using synthetic biology approaches to identify early CRC development, monitor
and report changes in the adenoma and CRC microenvironment, and prevent cancer progression. To achieve
the above objectives, engineered bacteria have to engraft and colonize the hostile luminal environment, sense
and distinguish an abnormal environmental signal, compute this signal, and express a reporter or a therapeutic
agent. However, appropriate vectors with these features remain lacking, constraining synthetic biology applica-
tions for cancer research. Importantly, CRC is highly associated with E. coli, for which we have many synthetic
biology tools. Furthermore, our preliminary proof-of-concept studies have revealed that native E. coli can be
engineered to perpetually colonize fully conventional (i.e. non-microbiome depleted) hosts and to execute func-
tions of interest, e.g., deconjugation of luminal bile acids. Deconjugated bile acid and resultant farnesoid X re-
ceptor (FXR) agonism can suppress CRC development, indicating a potential therapeutic use of engineered
native bacteria. Building on our strong supportive preliminary results, we will identify native E. coli from healthy,
adenoma, and CRC tissues of a genetic model of CRC and engineer them to detect and treat CRC in response
to the cancer microenvironment. Furthermore, we will characterize the effects of different tumor environment
factors on the colonization and performances of engineered native E. coli in the colon organoid model in an
organ-on-chip with the support of mathematical modeling, thereby identifying specific CRC signals for program-
ming the responses of engineered native E. coli as CRC reporters and therapeutics. Finally, we will engineer
native bacteria to detect and attenuate the progression of CRC by quantitatively reporting the level of CRC-
related cysteine proteases and selectively inhibiting their activity. The research described in this proposal will
generate new, much-needed synthetic biology vectors that can be developed as biosensors and therapeutics of
adenoma and CRC, as well as many other diseases. Furthermore, this project will enrich our fundamental
knowledge about the CRC-microbiome relationship and elucidate the roles of cysteine proteases in CRC pro-
gression and treatment.
项目总结/摘要
尽管其总体发生率下降,但结直肠癌(CRC)仍然是第四大常见原因
在美国癌症死亡人数。不幸的是,流行病学研究表明,inci-
在50岁以下的人群中,没有进行常规筛查。此外,CRC检测是困难的
在高危人群中,包括具有遗传倾向的人群(如家族性腺瘤性息肉病),
特征(例如炎症性肠病)或某些人口统计学特征(例如黑人)。由此可见,有一
迫切需要开发创新的解决方案,以早期发现CRC和预防
从腺瘤到CRC的转变。为了满足这一需求,我们的跨学科研究团队将开发
使用合成生物学方法的基因工程细菌,以识别早期CRC发展,监测
并报告腺瘤和CRC微环境的变化,防止癌症进展。实现
为了达到上述目的,工程菌必须植入并定殖在不利的管腔环境中,
并区分异常环境信号,计算该信号,并表达报告基因或治疗基因,
剂然而,具有这些特征的合适载体仍然缺乏,限制了合成生物学的应用。
为癌症研究做贡献。重要的是,CRC与E.大肠杆菌,我们有许多合成的
生物学工具此外,我们初步的概念验证研究表明,原生E。大肠杆菌可以是
被设计为永久地定殖完全常规的(即非微生物组耗尽的)宿主,并执行功能,
感兴趣的内容,例如,管腔胆汁酸的去结合。去共轭胆汁酸和所得的法尼醇X re-binding
受体(FXR)激动可以抑制CRC的发展,表明工程改造的FXR具有潜在的治疗用途。
原生细菌基于我们强有力的支持性初步结果,我们将确定天然E。大肠杆菌,
腺瘤和CRC组织,并对其进行工程改造以检测和治疗CRC,
到癌症微环境。此外,我们将描述不同肿瘤环境的影响,
影响工程天然E.大肠杆菌在结肠类器官模型中,
芯片上器官的数学建模的支持,从而识别特定的CRC信号的程序,
观察工程天然E.大肠杆菌作为CRC报告基因和治疗剂。最后,我们将工程师
通过定量报告CRC的水平来检测和减弱CRC的进展,
相关的半胱氨酸蛋白酶并选择性地抑制它们的活性。本提案中描述的研究将
产生新的,急需的合成生物学载体,可以开发为生物传感器和治疗,
腺瘤和CRC,以及许多其他疾病。此外,该项目将丰富我们的基础知识,
关于CRC-微生物组关系的知识,并阐明半胱氨酸蛋白酶在CRC前体中的作用。
回归与治疗
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Amir Zarrinpar其他文献
Amir Zarrinpar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Amir Zarrinpar', 18)}}的其他基金
Bacterial DNA as a Diagnostic Biomarker of Hepatocellular Carcinoma
细菌 DNA 作为肝细胞癌的诊断生物标志物
- 批准号:
10557105 - 财政年份:2022
- 资助金额:
$ 68.24万 - 项目类别:
The Role of Bile Salt Hydrolase in Glucose Metabolism
胆盐水解酶在葡萄糖代谢中的作用
- 批准号:
10365160 - 财政年份:2022
- 资助金额:
$ 68.24万 - 项目类别:
The Role of Bile Salt Hydrolase in Glucose Metabolism
胆盐水解酶在葡萄糖代谢中的作用
- 批准号:
10617180 - 财政年份:2022
- 资助金额:
$ 68.24万 - 项目类别:
Bacterial DNA as a Diagnostic Biomarker of Hepatocellular Carcinoma
细菌 DNA 作为肝细胞癌的诊断生物标志物
- 批准号:
10357369 - 财政年份:2022
- 资助金额:
$ 68.24万 - 项目类别:
Engineering Native E. coli to Detect, Report, and Treat Colorectal Cancer
改造天然大肠杆菌来检测、报告和治疗结直肠癌
- 批准号:
10700076 - 财政年份:2021
- 资助金额:
$ 68.24万 - 项目类别:
The Role of Altered Luminal Dynamics in OSA-Induced Atherosclerosis
管腔动力学改变在 OSA 诱发的动脉粥样硬化中的作用
- 批准号:
10273745 - 财政年份:2021
- 资助金额:
$ 68.24万 - 项目类别:
The Role of Altered Luminal Dynamics in OSA-Induced Atherosclerosis
管腔动力学改变在 OSA 诱发的动脉粥样硬化中的作用
- 批准号:
10455260 - 财政年份:2019
- 资助金额:
$ 68.24万 - 项目类别:
The Role of Altered Luminal Dynamics in OSA-Induced Atherosclerosis
管腔动力学改变在 OSA 诱发的动脉粥样硬化中的作用
- 批准号:
10217244 - 财政年份:2019
- 资助金额:
$ 68.24万 - 项目类别:
The Role of Altered Luminal Dynamics in OSA-Induced Atherosclerosis
管腔动力学改变在 OSA 诱发的动脉粥样硬化中的作用
- 批准号:
10884617 - 财政年份:2019
- 资助金额:
$ 68.24万 - 项目类别:
The Role of Altered Luminal Dynamics in OSA-Induced Atherosclerosis
管腔动力学改变在 OSA 诱发的动脉粥样硬化中的作用
- 批准号:
10456644 - 财政年份:2019
- 资助金额:
$ 68.24万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 68.24万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 68.24万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 68.24万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 68.24万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 68.24万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 68.24万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 68.24万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 68.24万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 68.24万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 68.24万 - 项目类别:
Research Grant